Pseudocirrhosis in Metastatic Breast Cancer

Pseudocirrhosis denotes radiological and clinical changes in the liver that mimic true cirrhosis but arise rapidly in patients with metastatic breast cancer rather than from chronic liver disease. Characterised by nodular hepatic contour, capsular retraction and signs of portal hypertension, it typically reflects extensive metastatic infiltration or a desmoplastic reaction to systemic therapy. Common clinical features include ascites, splenomegaly, oesophageal varices and hepatocellular dysfunction. Although the underlying mechanisms remain incompletely understood, both tumour burden and chemotherapy-induced fibrosis appear to contribute. The condition often develops after multiple lines of anticancer treatment, notably alkylating agents, taxanes and targeted therapies. Pseudocirrhosis not only poses diagnostic challenges—requiring differentiation from viral, alcoholic or autoimmune cirrhosis—but also substantially alters management: the onset of portal hypertension may necessitate dose reductions, therapy interruptions or supportive interventions such as diuretics, endoscopic variceal ligation and transjugular intrahepatic portosystemic shunt placement. Prognostically, the emergence of pseudocirrhosis is associated with reduced survival, reflecting both the advanced stage of disease and complications of impaired hepatic reserve. Early recognition is therefore crucial to optimise both oncological and hepatological care pathways.

Research from Nature Portfolio

A comprehensive systematic review and meta-analysis evaluated 389 pseudocirrhosis cases across 62 studies and confirmed that approximately 80% of affected individuals had metastatic breast cancer. Most patients exhibited at least one manifestation of portal hypertension, with ascites present in the majority. The analysis highlighted a median survival of only two months following diagnosis of pseudocirrhosis, underlining its aggressive course. It also identified that patients frequently receive three or more lines of systemic therapy before onset, implicating cumulative treatment-related fibrosis alongside tumour infiltration. The work emphasised the need for standardised criteria to define pseudocirrhosis and recommended prospective studies to elucidate pathophysiological drivers and optimal management strategies.

Pseudocirrhosis in Metastatic Breast Cancer publication trend

The graph below shows the total number of articles in pseudocirrhosis in metastatic breast cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Pseudocirrhosis: A rapid onset cirrhosis-like condition in patients with hepatic metastases, marked by nodular liver contour and portal hypertension without chronic liver disease.

Portal hypertension: Elevated pressure within the portal venous system leading to ascites, splenomegaly and varices.

Desmoplastic response: Fibrotic reaction of stromal tissue around tumour cells, contributing to altered organ architecture.

Ascites: Pathological accumulation of fluid within the peritoneal cavity, often a sign of portal hypertension or liver dysfunction.

Hepatic metastases: Secondary malignant deposits in the liver originating from a primary breast tumour.

References

1. Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis. Scientific Reports (2022).
2. Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center. Frontiers in Oncology (2021).
3. Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report. Journal of Medical Case Reports (2010).